FGF401-(roblitinib)

oral reversible-covalent FGFR4 kinase inhibitor

first sel. FGFR4i in clinical studies; for HCC

from biochemical HTS and SBDD

J. Med. Chem., Oct. 1, 2020

Novartis, Basel, CH

FGF401 (roblitinib) is a highly selective, reversible-covalent inhibitor of the kinase FGFR4, a receptor that can drive progression of certain cancers. The Novartis team found that the FGFR4 protein has…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks